Investor Relations
Catalyst is a specialty biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system (CNS), with a focus on the treatment of addiction, infantile spasms, epilepsy and other CNS indications. Catalyst is developing vigabatrin (vi•gá•ba•trin, designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine and other addictive substances. Catalyst is also developing a more potent vigabatrin analogue (designated CPP-115 by Catalyst) for the treatment of cocaine addiction, infantile spasms and epilepsy, as well as other addiction and CNS indications. Catalyst believes that it controls all current intellectual property for drugs like CPP-109 and CPP-115 whose primary mechanism of action relates to GABA aminotransferase(GABA-AT), which is also known as GABA transaminase (GABA-T).
Annual Reports & Proxy Statement
View all »
Recent Releases
View all »Events & Presentations
03/11/12
ROTH Capital Partners 24th Annual Growth Stock Conference
03/05/12
Cowen and Company 32nd Annual Health Care Conference



